6 February 2018
Sofitel Legend Amsterdam The Grand
2017 Presenting Companies
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
Atlas Genetics (UK)
Atlas Genetics is a diagnostics company focused on ultra-rapid (≤ 30 mins) POC molecular tests for infectious diseases and genotyping. The initial commercial focus is on sexually transmitted infections, initially for chlamydia and gonorrhoea, which represents a 67 million tests per year market with well-established regulatory path and reimbursement www.atlasgenetics.com
BioClin Therapeutics (USA)
BioClin is developing a first-in-class anti-FGFR3 antibody (B-701), licensed from Genentech. B-701 is currently being evaluated in the treatment of metastatic bladder cancer. There remains a significant unmet medical need in this target population, even with the recent approvals of atezolizumab and nivolumab.
BioNTech AG is a fully integrated biotech company pioneering individualised cancer immunotherapies. It has assembled all key immunotherapy platform technologies under one roof based upon the notion that future cancer treatments will be determined by genomic sequencing of each patient’s tumour. BioNTech has a revolutionary clinical pipeline of currently four products in the clinic with an additional three products expected to enter the clinic in the next 12 months: most of the pipeline is unpartnered. Its partnering strategy yielded $450 million in upfront and near-term payments across five collaborations executed over a period of 18 months. The company has built in-house clinical personalised therapy manufacturing platforms and uses latest advances in artificial intelligence, robotics and automation for commercial manufacture.
AG is a fully integrated biotech company pioneering individualised cancer immunotherapies. It has assembled all key immunotherapy platform technologies under one roof based upon the notion that future cancer treatments will be determined by genomic sequencing of each patient’s tumour. BioNTech has a revolutionary clinical pipeline of currently four products in the clinic with an additional three products expected to enter the clinic in the next 12 months: most of the pipeline is unpartnered. Its partnering strategy yielded $450 million in upfront and near-term payments across five collaborations executed over a period of 18 months. The company has built in-house clinical personalised therapy manufacturing platforms and uses latest advances in artificial intelligence, robotics and automation for commercial manufacture.
Bone Therapeutics (BEL)
Bone Therapeutics is a leading biotechnology company specialising in cell therapy products for the treatment of orthopaedic conditions and bone diseases. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products consisting of osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique – a unique proposition in the market. Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families.
Cardior Pharmaceuticals (GER)
Cardior is a spin-off of Hannover Medical School and dedicated to becoming the world leader in design, research and development of non-coding RNA-based therapeutics for cardiovascular diseases. Cardior aims to market its products in collaboration with a strategic pharma partner after clinical proof-of-concept data in patients with myocardial infarction and heart failure.
Curetis is a molecular diagnostics company that focuses on the development and commercialisation of reliable, fast and cost-effective products for diagnosing severe infectious diseases. To date, Curetis has raised €44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over €63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to €25 million.
eTheRNA immunotherapies is focusing on therapies that activate the immune system through a specific focus on programming dendritic cells (DC) with synthetic mRNA. Encouraged by the impressive complete response rate (>20%) of the combination therapy including TriMix-DC and ipilimumab in patients with advanced melanoma, the company is committed to establishing its TriMix technology as the gold standard in the wider area of onco-immunotherapy.
Evotec AG (GER)
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer’s disease, with Sanofi in the field of diabetes with Pfizer in the field of tissue fibrosis and with Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com.
Founded in 2006, EyeSense is a spin-off venture from Novartis AGs eye care company CIBA Vision. The company has developed a unique and revolutionary glucose sensor technology that has the potential to transform existing measurement techniques. The sensor can be placed at the tip of a tiny optical fibre that is inserted under the skin of the abdomen or the upper arm. Clinical trials have demonstrated a superior accuracy and long-term stability of the new glucose sensor technology. This will allow entry into the very lucrative emerging and growing glucose monitoring market (CGM).
G-Therapeutics is a spin-off of EPFL, the technical university of Lausanne, based upon the academic work of Prof Grégoire Courtine, who has dedicated his scientific career to investigate methods to improve rehabilitation of people with spinal cord injury.
Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This point-of-care test provides doctors with accurate information on the liver function capacity to support decision-making in tailoring the medical treatment for each patient and to improve patient outcomes.
- Spin-off of the Institut Paoli-Calmette in Marseille
- Founded by Prof. Daniel Olive, a renowned pioneer in the area of co-signalling pathways
- Developing a new generation of agonist and antagonist therapeutic antibodies with applications in immuno-oncology (novel checkpoint inhibitors) and autoimmune diseases
Immunic Therapeutics (GER)
Immunic was founded in April 2016 with the purpose of advancing promising drug development projects to clinical proof-of-concept. The focus of Immunic is the development of orally available, small-molecule immune modulators to treat immune and autoimmune diseases such as inflammatory bowel disease (IBD) or psoriasis.
iTeos Therapeutics (BEL)
iTeos, a spin-off of Ludwig Cancer Research and de Duve Institute, is an immune-oncology company with rapidly advancing programmes for hot and cold tumours. iTeos develops a proprietary pipeline targeting A2A receptor, immune checkpoints and non-immunogenic tumours and partnered with Pfizer for its IDO1 programme, which is now in Phase I.
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its
immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is GLASSIA®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA®, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency for which a MAA was submitted to the EMA after completing a pivotal Phase 2/3 clinical trials in
Europe. Kamada has also completed its Phase 2 clinical trials in the U.S for the treatment of AAT deficiency with inhaled AAT. In addition, Kamada’s intravenous AAT is in development for other indications such as type-1 diabetes, GvHD and prevention of lung transplant
rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.
Kiadis Pharma (NL)
Kiadis Pharma is a clinical stage company developing therapies for patients with late stage blood cancers and non-malignant blood disorders. ATIR101™ is a cell based medicinal product manufactured from mismatched family members to allow for T-cell infusions after stem-cell transplantation to strengthen the patients immune system w/o eliciting life threatening acute severe chronic graft versus host disease.
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration. Kuros Biosciences’ most advanced programmes are focussed in the areas of sealants and orthobiologics.
Luxendo is a recent spin-off from EMBL in Heidelberg, commercialising advanced Single Plane Illumination Microscopes (SPIM). Compared with modern state-of-the-art confocal or wide-field microscopes, SPIM technology allows for significantly reduced sampling times at comparable and even higher resolution with highly reduced damaging side effects on the living objects investigated. Nature Methods has characterised SPIM technology, also known as light sheet microscopy, as ‘Method of the Year 2014’.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
Merus started operations in 2006 and listed on Nasdaq in May 2016. In December 2016, Merus closed a collaboration with Incyte that included $200 million upfront consideration for licence and equity. Merus discovers and develops differentiating of bispecific antibodies aimed at substantially prolonging the lives of cancer patients.
Mint Solutions/MedEye (NL)
MedEye builds tools to help nurses and doctors provide exceptional care for patients. The first product ensures that patients get the right medication at the right time, improving safety, saving lives and reducing the costs of medication errors worldwide.
Miracor Medical Systems (AUT)
Miracor develops disruptive solutions to treat severe heart diseases, striving to bring back cardiac patients to normal life. Miracor has developed the PiCSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System, a breakthrough technology platform designed to improve the clinical outcome of patients with impaired cardiac function.
Globally 15M people suffer from stroke each year. Endovascular treatment with Stentrievers has recently been proven to improve outcomes for large vessel ischemic stroke. Neuravi’s experienced team seeks to advance stroke treatment in collaboration with leading clinicians. Research into clot and the clinical challenge is the foundation of technology development, driving innovation that strives to improve outcomes. www.neuravi.com
Nouscom is an IO biotech, founded in 2015, with operations in Switzerland and Italy dedicated to the development of next-generation cancer vaccines. Nouscom raised €12 million from Versant Ventures and LSP. Nouscom’s founders come from Okairos, sold to GSK in 2013, where they developed a genetic vaccine platform for infectious diseases (HIV, HCV, malaria, Ebola, RSV).
Orphazyme is a clinical-stage company with its lead programme, arimoclomol, in clinical development for lysosomal and other protein-misfolding diseases. Arimoclomol is in development for four rare protein-misfolding diseases with a very high unmet need: Niemann-Pick type C (NPC), Gaucher disease, sporadic inclusion body myositis and ALS.
For more information, please visit www.orphazyme.com.
OxThera AB (SWE)
OxThera focuses on the development of drugs for the treatment of primary hyperoxaluria (PH), an ultra-orphan paediatric fatal disease. Untreated patients with PH advance to end-stage renal disease around age 20. There are currently no drugs available on the market for treatment of this devastating disease. The prime drug candidate is called Oxabact®, which has shown positive effect in a recent Phase II study and is now up for its registration study. Oxabact® has shown an excellent safety profile.
Pantarhei Oncology (NED)
Pantarhei Bioscience/Oncology: Pantarhei Bioscience develops patent-protected innovative medical uses of existing hormones and steroidal drugs in women’s health, whereas Pantarhei Oncology focuses on breast and prostate cancer. Both Pantarhei companies develop new treatment concepts until proof-of-concept in the human. Thereafter, the products are licensed out for final development and marketing.
Probiodrug AG is a publicly traded (Euronext, PBD) company dedicated to the research and development of new therapeutic products for the treatment of Alzheimer’s disease. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) via inhibition of Glutaminyl Cyclase (QC) and via an antibody. It has a broad basis of medical use and composition of matter patents.
For more information, please visit www.probiodrug.de
Tigenix is considered to be among the most advanced cell therapy companies in the world, with lead product candidate, Cx601, showing positive Phase III results, having met primary endpoint at week 24 (published in the Lancet) and long-term efficacy at week 52. Cx601, being developed for complex perianal fistulas in Crohn’s Disease, has been granted Orphan Drug Designation in Europe and expects to receive marketing authorization by year-end 2017. TiGenix has licensed Cx601 (ex-US) to Takeda who will launch Cx601 in Europe after marketing approval has been granted.
· Compelling story, near-term milestones, strong balance sheet
· Recently completed US IPO raised $36M – positioned to advance on milestones
· Dual-listed on Nasdaq and Euronext Brussels with ticker “TIG”
· Supported by specialized institutional investors on both sides of the Atlantic
· Important industry investors Grifols and Takeda
· Recent partnership with Takeda for up to €350M for Cx601, plus €25M up front
· Near-term milestone payment of €15M from Takeda expected in 2H2017 with MA
· Takeda invested €10M equity and exercised follow-on options for Japan and Canada
· Initiation of global pivotal Phase III trial for Cx601 US registration in 1H2017
· Pipeline of other relevant late-stage assets
· Recently initiated Phase I/II clinical trial for Cx61 in sever sepsis
· Strong financial position (estimated Cash of €75M at 31 Dec. 2016)
· Market Cap = €180M
For more information, please visit our website: www.TiGenix.com
uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe genetic diseases.
We are advancing a focused pipeline of innovative gene therapies and have established clinical proof-of-concept in our lead indication, hemophilia B, and preclinical proof-of-concept in Huntington’s disease. Our pipeline of adeno-associated virus (AAV)-based gene therapies is developed both internally and through multiple collaborations using our innovative, modular technology platform, including our proprietary commercial-grade industry-leading manufacturing capabilities in two geographical locations. Through our collaborations and the strategic partnership with Bristol-Myers Squibb to develop gene therapies for cardiovascular diseases, we have made the next step towards developing gene therapies targeting chronic and degenerative diseases that affect larger populations.
Vivasure Medical (IRE)
Percutaneous large (12F+) arteriotomy closure is an area of unmet clinical need which is growing rapidly, driven by the expanding penetration of procedures such as Transcatheter Aortic Valve Repair. Vivasure’s technology enables a fully percutaneous approach for these patients, yielding significant clinical and economic benefits for patients, physicians and payers.
Xeltis is reinventing the heart valve and pioneering a new restorative approach in cardiovascular treatment. Its heart valves offer the body a second chance to form new functioning valves with the patient’s tissue before bioabsorbing. They enable cardiovascular restoration within the body. This revolutionary therapeutic approach is called Endogenous Tissue Restoration.
Zealand Pharma (DEN)
Zealand Pharma A/S is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of product candidates that primarily target specialty diseases with significant unmet needs.